Visa Inc. saw spending growth rise 10.5 percent to $2.93 trillion in the fiscal fourth quarter, the slowest since the depths of the pandemic Visa posted less than 5 percent for the first fiscal quarter of 2021.
Shares gained as profit exceeded analysts’ expectations.
The volume was shy of the 11 percent increase Bloomberg analysts were expecting and a decrease from the 12 percent growth the firm reported for the previous three months
According to Visa CEO Al Kelly, while some short-term uncertainty exists, they remain confident in Visa’s long-term growth trajectory across consumer payments, new flows, and value-added services,”
Visa and its rivals are facing tough comparisons with a year earlier when spending jumped as economies opened back up as the pandemic began to recede.
When planning for 2023, Visa “did not factor in a steep economic downturn or recession,” Kelly said on a conference call with analysts. If such a decline occurs, “it will have some impact.”


The Beauty Beneath the Expressway: A Journey from Self to Service
Nvidia-Groq AI Chip Deal Faces U.S. Antitrust Probe
OpenAI Targets Specialized Industries as Enterprise AI Demand Grows
6 simple questions to tell if a ‘finfluencer’ is more flash than cash
Japanese Yen Nears Seven-Month High as Oil Approaches $100
Locked up then locked out: how NZ’s bank rules make life for ex-prisoners even harder
Qualcomm Stock Jumps on Amazon AI Chip Deal
Debate over H-1B visas shines spotlight on US tech worker shortages
Enflame Shares Surge 200% in Shanghai AI Chip Debut
Google promotes ‘teacher approved’ apps for kids. Here’s what parents should know
Nvidia Plans 2GW Australia AI Data Center Expansion by 2027
Google Revamps EU Search Results to Meet DMA Rules
Every generation thinks they had it the toughest, but for Gen Z, they’re probably right
Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that
The ghost of Robodebt – Federal Court rules billions of dollars in welfare debts must be recalculated
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 



